Medicine
More
-
NEW YORK-- Shares of Halozyme Therapeutics Inc. climbed Thursday after the company reported clinical trial data for an experimental cancer drug. Halozyme's drug development partners include Roche, Pfizer, Baxter International Inc., and ViroPharma Inc..
-
NEW YORK-- Shares of Halozyme Therapeutics Inc. climbed Thursday after the company reported clinical trial data for an experimental cancer drug. Halozyme's drug development partners include Roche, Pfizer, Baxter International Inc., and ViroPharma Inc..
-
NEW YORK-- Shares of Oncothyreon Inc. fell Thursday after the drug developer announced new clinical trial data about an experimental lung cancer treatment that failed to improve overall survival rate. THE SPARK: Oncothyreon said that it identified some patients who appeared to live longer after treatment with Stimuvax.
-
RALEIGH, N.C.-- Legislation that attempts to prevent people from suing North Carolina food manufacturers, sellers and advertisers by claiming their products made them overweight has passed one General Assembly chamber. Brian Brown of Greenville says the measure is a commonsense way to eliminate frivolous lawsuits.
-
NEW YORK-- A deadly new respiratory virus related to SARS has apparently spread from patients to health care workers in eastern Saudi Arabia, health officials said Wednesday. The Ministry of Health in Saudi Arabia told world health officials that two health care workers became ill this month after being exposed to patients with the virus.
-
CHICAGO/ NEW YORK, May 15- Shares of drugmaker Bristol-Myers Squibb Co rose to a 10- year high on Wednesday ahead of results of an early stage trial for its new melanoma treatment, with heavy betting in the options market suggesting investors see more gains in the stock.
-
NEW YORK, May 15- Swiss drugmaker Roche Holding AG is exploring a sale of its blood glucose meters business, three people familiar with the matter told Reuters on Wednesday, as the industry grapples with increased competition and reimbursement pressure.
-
CHICAGO/ NEW YORK, May 15- Shares of drugmaker Bristol-Myers Squibb Co rose to a ten-year high on Wednesday ahead of results of an early stage trial for its new melanoma treatment, with heavy betting in the options market suggesting investors see more gains in the stock.
-
A 65-year-old couple retiring this year would need $220,000 on average to cover medical expenses, an 8 percent decrease from last year's estimate. But most people estimate just a fraction of that.
-
ZURICH, May 15- Swiss drugmaker Roche hopes data published this week will show it has a viable follow-on product to help fend off cheaper competition for its best-selling cancer drug, which loses patent protection in Europe later this year.
-
This marks the first companion diagnostic that detects epidermal growth factor receptor gene mutations to be approved by the U.S. Food and Drug Administration, the agency said.
-
The number of women choosing to have preventive mastectomies has risen by almost 50 percent in recent years, and surveys show they are happy with the decision.
-
DURHAM, N.C.-- Drug developer Chimerix Inc. said Monday it took a larger loss in the first quarter on costs related to redeemable preferred stock. Chimerix conducted its initial public offering in April, and the company said it raised $117.9 million before expenses and discounts. Shares of Chimerix rose 70 cents, or 3.5 percent, to $20.75 in morning trading.
-
Under President Barack Obama's health care law, where you live could make a huge difference in what you'll pay for medications.
-
CNBC's Herb Greenberg reports on the question facing Intuitive Surgical. The company alerted hospitals of a potential issue with one of its instruments.
-
INDIANAPOLIS-- Eli Lilly and Co. said Friday it will stop development of an experimental cancer drug after it failed in a late-stage clinical trial. The company will take a charge of about $30 million in the second quarter, but didn't make changes to its full-year guidance. Shares of Eli Lilly added 4 cents to $54.60 in afternoon trading.
-
May 10- The U.S. Food and Drug Administration has approved a new drug to treat chronic obstructive pulmonary disease, a condition often associated with smoking that can include emphysema, chronic bronchitis, or both. The drug, Breo, is an inhaled treatment made by British drugmaker GlaxoSmithKline Plc and Theravance Inc of the United States.
-
May 10- Eli Lilly and Co said it will end development of an experimental cancer drug after it failed in a late-stage trial to delay a worsening of symptoms in patients with lymphoma.
-
SEATTLE-- Dendreon Corp. said Thursday that sales of its prostate cancer therapy Provenge fell in the first quarter because of increased competition from two newer drugs. Net revenue from Provenge fell 18 percent to $67.6 million, Dendreon said. Dendreon said it lost $72 million, or 48 cents per share, in the three months ended March 31.
-
Massachusetts has had Romneycare since 2006. And, while it's different in some ways from Obamacare, it offers insight into what's ahead for US health care.